TAIPEI, July 28, 2026
Dasher Neuroscience Holdings Inc. has successfully completed patient enrollment in its global Phase 2 clinical trial evaluating YA-101, the company’s lead AI-developed drug candidate for the treatment of Multiple System Atrophy (MSA), marking a significant milestone in the advancement of therapies for one of the world’s most devastating rare neurodegenerative diseases. The AI-driven biopharmaceutical company enrolled 90 patients across multiple clinical sites in the United States, Japan, and Taiwan, strengthening its efforts to accelerate the development of a potential first-in-class treatment for MSA. The completion of enrollment positions the company to generate top-line clinical data in the first quarter of 2027, while simultaneously advancing global out-licensing discussions and planning a multinational Phase 3 clinical trial. The achievement reflects the growing role of artificial intelligence in drug discovery and reinforces Dasher Neuroscience’s commitment to delivering innovative therapies for central nervous system disorders with significant unmet medical needs. If successful, YA-101 could become a groundbreaking disease-modifying therapy for patients who currently have limited treatment options beyond symptomatic care.
Global Phase 2 Trial Reaches Full Patient Enrollment
The global, multicenter, randomized, double-blind, placebo-controlled, dose-escalation Phase 2 clinical trial has now completed enrollment of 90 participants diagnosed with Multiple System Atrophy, including both the Parkinsonian subtype (MSA-P) and the Cerebellar subtype (MSA-C) according to Movement Disorder Society (MDS) diagnostic criteria. Conducted across leading research centers in the United States, Japan, and Taiwan, the study is designed to comprehensively evaluate the safety, tolerability, pharmacokinetics, and clinical efficacy of YA-101 in patients aged 30 years and older. The trial’s primary endpoint focuses on assessing the incidence and severity of Adverse Events (AEs), while secondary endpoints include pharmacokinetic (PK) analysis, improvements measured through the Unified Multiple System Atrophy Rating Scale (UMSARS), and patient mobility assessed using the 10-Meter Walk Test. According to Dr. Jane Tseng, Chief Executive Officer of Dasher Neuroscience, completing enrollment represents a major development milestone that will provide critical clinical evidence supporting future regulatory advancement, commercialization planning, and strategic licensing partnerships worldwide.
FDA Fast Track Designation Supports Regulatory Progress
YA-101 is a New Chemical Entity (NCE) and an innovative D-amino acid oxidase inhibitor (DAOI) developed to reduce neuroinflammation, suppress inflammatory cytokines, and enhance neuroplasticity, potentially slowing disease progression rather than simply managing symptoms. The investigational therapy has already received several important regulatory recognitions, including U.S. FDA Fast Track Designation and Orphan Drug Designation (ODD) from regulatory authorities in the United States, Japan, and the European Union. These designations recognize the urgent need for new treatments targeting rare diseases and may facilitate accelerated regulatory interactions throughout clinical development. In parallel with ongoing clinical evaluation, Dasher Neuroscience is actively pursuing global licensing partnerships while preparing a global Phase 3 multicenter study, reflecting confidence in the commercial and clinical potential of YA-101. Beyond its lead program, the company’s expanding CNS pipeline includes YA-102 for Parkinson’s disease, YA-201 targeting Alzheimer’s disease, and YA-301 for schizophrenia, demonstrating its long-term commitment to AI-driven neuroscience innovation.
Advertisement
AI-Driven Innovation Targets Critical Rare Disease Need
Multiple System Atrophy (MSA) is a rare, rapidly progressive, and fatal neurodegenerative disorder that typically develops in individuals during their 50s, causing severe impairment of movement, balance, and autonomic nervous system function. Nearly 80% of patients become severely disabled within five years of diagnosis, while average survival is only six to ten years. Despite its devastating impact, no approved disease-modifying therapies currently exist, leaving patients dependent on supportive treatments that only relieve symptoms. Global prevalence is estimated at approximately 5 cases per 100,000 people, affecting 15,000–50,000 individuals in the United States, 18,000–70,000 across the European Union, 12,000 in Japan, and around 2,000 in Taiwan. By combining artificial intelligence-driven drug discovery, innovative molecular design, and global clinical development, Dasher Neuroscience aims to deliver a transformative therapy capable of addressing this significant unmet medical need. Successful completion of the ongoing Phase 2 trial could position YA-101 as one of the most promising emerging treatments in rare neurological disease research while further demonstrating the growing impact of AI-enabled biopharmaceutical innovation.
Source: Dasher Neuroscience press release
